FAST-Acting Sub-perception Therapy (FAST™) Clinical Summary

FAST Therapy is backed by Published Real-World Data¹, Preclinical Data² and Computational Modeling³

Published Real World Data Demonstrate Profound Paresthesia-Free Pain Relief in Minutes with FAST Therapy¹

- After activation of FAST Therapy
  - Overall pain was reduced by a mean 5.2 ± 0.3 points versus pre-FAST Therapy activation within 11.2 ± 1.9 minutes (N = 34).†
  - Overall pain was reduced by a mean 7.0 ± 0.4 points (N = 41, p < 0.0001) at 6 month follow-up.

Additional Real World FAST Data Demonstrates Significant and Sustained Improvement in Functional Outcomes and Quality of Life⁴

- At last follow-up (mean = 412 ± 338 days)
  - Improved functional outcomes and quality of life reported with use of FAST Therapy
  - Improvement in disability: A 36.1-point mean reduction in ODI. Improvement in one disability level (e.g. from severe to moderate disability)
**FAST provides clinically meaningful pain relief while preserving device longevity and improving battery consumption management**

- All FAST stimulation options show >50% responder rate.
- FAST responders achieve profound pain relief (NRS <2) with the use of all FAST stimulation options.
- FAST stimulation energy consumption is 95% lower compared to conventional Sub-perception SCS.

**New Prospective Data Confirms FAST Immediate Pain Relief and Demonstrates High FAST Responder Rate**

- FAST responders achieved maximum paresthesia-free pain relief within 4.9 ± 1.5 minutes.
- FAST Achieved a 92% Responder Rate and an 85% Profound Responder Rate (>75% Relief) within minutes.